Alternatives to Rinvoq (Upadacitinib)
For patients requiring an alternative to Rinvoq, the specific replacement depends entirely on the indication: in rheumatoid arthritis, other JAK inhibitors (tofacitinib, baricitinib) or biologics (TNF inhibitors, abatacept, IL-6 inhibitors) are appropriate; in ulcerative colitis, infliximab, vedolizumab, ozanimod, etrasimod, risankizumab, or guselkumab represent higher-efficacy alternatives; and in atopic dermatitis, dupilumab, tralokinumab, or abrocitinib are recommended alternatives.
Rheumatoid Arthritis Alternatives
Other JAK Inhibitors
- Baricitinib (4 mg daily) is an effective alternative that showed superior efficacy to adalimumab when combined with methotrexate, though superiority was primarily seen in patient-reported outcomes rather than joint counts 1.
- Tofacitinib (5 mg twice daily) represents another JAK inhibitor option, though it carries similar warnings regarding venous thromboembolism (VTE) risk, particularly at higher doses and in patients with cardiovascular risk factors 2.
- Both baricitinib and tofacitinib have demonstrated similar overall efficacy to upadacitinib, with no clear evidence that one JAK inhibitor is superior to another in terms of clinical, functional, or structural outcomes 1.
Biologic DMARDs
- TNF inhibitors (infliximab, adalimumab, golimumab, certolizumab, etanercept) remain first-line biologic options when combined with methotrexate in patients with poor prognostic factors 3.
- Abatacept (T-cell costimulation inhibitor) is an alternative, though upadacitinib demonstrated superiority to abatacept in achieving DAS28-CRP remission (30.0% vs 13.3%) at week 12 4.
- IL-6 receptor inhibitors (tocilizumab, sarilumab) represent another mechanistic class with proven efficacy 3.
Critical Safety Consideration
- The 2020 EULAR guidelines emphasize that when selecting between biologics and JAK inhibitors, the decision should be based on contraindications, patient preference, and costs, as efficacy is generally comparable 2.
- VTE risk is a class effect of JAK inhibitors, occurring especially in patients with prior VTE history, high BMI, hormone replacement therapy, and advanced age 2, 5.
Ulcerative Colitis Alternatives
Higher-Efficacy Medications (Preferred)
The 2024 AGA guidelines stratify alternatives by efficacy tier 6:
Higher-efficacy options include:
- Infliximab - provides 170 more remissions per 1000 patients compared to placebo (moderate certainty evidence) 6.
- Vedolizumab (anti-integrin) - gut-selective mechanism with favorable safety profile 6.
- Ozanimod and etrasimod (S1P receptor modulators) - oral alternatives with moderate desirable effects 6.
- Risankizumab and guselkumab (anti-IL23 antibodies) - newer biologics with moderate desirable effects 6.
Intermediate-Efficacy Medications
- Golimumab (TNF antagonist) 6.
- Ustekinumab (IL-12/23 inhibitor) - associated with 32% lower risk of serious infections compared to TNF antagonists 6.
- Tofacitinib (JAK inhibitor) - though FDA recommends use only after TNF antagonist failure 6.
- Filgotinib (JAK inhibitor) - conditional recommendation due to smaller magnitude of benefit 6.
Lower-Efficacy Option
- Adalimumab - conditional recommendation with trivial to small desirable effect over no intervention 6.
Key Implementation Considerations
- JAK inhibitors have restricted first-line use: FDA recommends their use only after TNF antagonist failure or intolerance 6.
- In Europe, the EMA recommends cautious first-line JAK inhibitor use in patients ≥65 years, current/previous smokers, or those with cardiovascular disease history 6.
- Biosimilars of infliximab, adalimumab, and ustekinumab are considered equivalent to originators 6.
Atopic Dermatitis Alternatives
Biologic Therapies (Preferred First-Line)
- Dupilumab (IL-4/IL-13 inhibitor) - strong recommendation with moderate certainty evidence as the established first-line biologic 7.
- Tralokinumab (IL-13 inhibitor) - strong recommendation with moderate certainty evidence, though may be less effective than dupilumab 7.
Other JAK Inhibitors
- Abrocitinib - strong recommendation with moderate certainty evidence, FDA-approved after failure of other systemic therapies 7.
- Baricitinib - strong recommendation with moderate certainty evidence, though not FDA-approved for atopic dermatitis (off-label use) 7.
Comparative Effectiveness
- Network meta-analyses indicate that abrocitinib 200 mg and upadacitinib 30 mg may be more effective than dupilumab and baricitinib as second-line therapies 8.
- Real-world evidence shows EASI-75 achievement rates of 75% for abrocitinib, 51% for baricitinib, and 83% for upadacitinib at 16 weeks across all doses 9.
Safety Profile Comparison
- Acne and herpes simplex virus (HSV) are the most common adverse events across all JAK inhibitors, with acne most prevalent with abrocitinib 100 mg (21%) and HSV with upadacitinib 30 mg (6%) 9.
- Dupilumab and tralokinumab have distinct safety profiles without the VTE, cardiovascular, or infection risks associated with JAK inhibitors 7.
Critical Contraindications and Monitoring for All JAK Inhibitor Alternatives
When considering any JAK inhibitor alternative to upadacitinib:
Absolute Contraindications
- Severe active infections including latent tuberculosis 5.
- Severe hepatic disease (Child-Pugh C) 5.
- Pregnancy or lactation (effective contraception required) 5.
- Active malignancy under treatment (excluding non-melanoma skin cancer) 5.
High-Risk Situations Requiring Caution
- VTE risk factors: prior VTE, inherited thrombophilia, age >65 years, obesity, recent surgery, immobility, estrogen use, smoking, uncontrolled hypertension, or concurrent COX-2 inhibitors 5.
- Recurrent VTE without therapeutic anticoagulation is a relative contraindication 5.
Mandatory Baseline Screening
- Complete blood count with differential 5.
- Hepatic transaminases (ALT/AST) 5.
- Renal function (creatinine clearance) 5.
- Lipid profile 5.
- Hepatitis B serology 5.
- Tuberculosis screening 5.
- Skin examination for non-melanoma skin cancer in at-risk individuals 5.